Android app on Google Play

Dendreon (DNDN) Competition Shadow Looms Larger After ASCO - Jefferies

June 4, 2012 7:45 AM EDT Send to a Friend
Get Alerts DNDN Hot Sheet
Price: $1.35 -6.25%

Rating Summary:
    3 Buy, 18 Hold, 12 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 16 | Down: 12 | New: 33
Trade DNDN Now!
Join SI Premium – FREE
Jefferies reiterated their Underperform rating and $5 price target on Dendreon (NASDAQ: DNDN) following strong data from competitors at ASCO.

The firm comments, "Provenge’s outlook takes another severe hit from Zytiga’s striking ~9-mo OS benefit over a higher placebo hurdle in the 302 trial for pre-chemo mCRPC. Given we believe MDV3100 could also match/beat Zytiga on OS, Provenge’s eventual relegation to a niche spot in an otherwise lucrative mkt is looking even likelier."

For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $6.76 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment